Julia A. Beaver

10.7k citations

131 papers · 4.8k indexed · 3 hit papers · h-index 39

Impact in

Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Lung Cancer Research Studies
Cancer Research top 1%
- Cancer Genomics and Diagnostics

Papers in

Cancer Research 53
- Cancer Genomics and Diagnostics 36
Oncology 62
- Cancer Immunotherapy and Biomarkers 27
- HER2/EGFR in Cancer Research 14

Co-authors: Richard Pazdur Marc R. Theoret Kirsten B. Goldberg Rajeshwari Sridhara Shenghui Tang Paul G. Kluetz Harpreet Singh Laleh Amiri‐Kordestani
Journals: Journal of Clinical Oncology (36 papers)Clinical Cancer Research (28 papers)The Oncologist (11 papers)JAMA Oncology (6 papers)New England Journal of Medicine (5 papers)
Partner nations: United States Canada Singapore

In The Last Decade

Julia A. Beaver

123 papers receiving 4.7k citations

Hit Papers

align trajectories log scale

Trends in the approval of cancer therapies by the FDA in the twenty-first century 2023 · 155 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 Nature Reviews Drug Discovery
2021 Clinical Cancer Research
2021 Clinical Cancer Research

Peers

Countries citing papers authored by Julia A. Beaver

Since Specialization

Citations

This map shows the geographic impact of Julia A. Beaver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia A. Beaver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia A. Beaver more than expected).

Fields of papers citing papers by Julia A. Beaver

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julia A. Beaver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia A. Beaver. The network helps show where Julia A. Beaver may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Julia A. Beaver, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Julia A. Beaver Line = papers co-authored together Julia A. Beaver links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum Clinical Cancer Research ·Kennya S. Ruiz-Veintimilla, Diana Bradford, Joaquim Parra Marujo, Pallavi S. Mishra‐Kalyani, Yuan Li Shen, Martin Creydt, Christophe Augur, G. F. Xu, R. E. Azuma, Rosane Charlab, Jeffrey Kraft, Sachia G. Khasar, Claudia P. Miller, Donna R. Rivera, Paul G. Kluetz, Richard Pazdur, Julia A. Beaver, Harpreet Singh, Martha Donoghue	2023	16
2	US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non–Small-Cell Lung Cancer Journal of Clinical Oncology ·Oladimeji Akinboro, Nicole Drezner, Anup Amatya, Jiho Yoo, Шапошников Александр Васильевич, Miao Zhao, Youwei Bi, Kwadwo Ameyaw Korsah, Bronwyn D. Mixter, Shenghui Tang, Erin Larkins, Richard Pazdur, Julia A. Beaver, Harpreet Singh	2023	23
3	FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Clinical Cancer Research ·袁瑞英, Erin Larkins, Etienne Coche De La Ferte, Pallavi S. Mishra‐Kalyani, Stephanie Aungst, Emily Wearne, Sriram Subramaniam, Andrea Kantrowitz, R. E. Azuma, Jielin Sun, Rosane Charlab, Christophe Augur, Elise van Obberghen, Rama Kamesh Bikkavilli, Soma Ghosh, Reena Philip, Julia A. Beaver, Harpreet Singh	2023	33
4	FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC Clinical Cancer Research ·Luckson Mathieu, Erin Larkins, A. K. Sinha, Pallavi S. Mishra‐Kalyani, Victor Augusto Dejard Mendonça da Rocha, Shyam Kalavar, Soma Ghosh, Kirsten B. Goldberg, Richard Pazdur, Julia A. Beaver, Harpreet Singh	2023	27
5	FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer Clinical Cancer Research ·Mirat Shah, Christy Osgood, Anup Amatya, Mallorie H. Fiero, William F. Pierce, Abhilasha Nair, 英介藏屋, Ken-ochi IJIRI, Bronwyn D. Mixter, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri‐Kordestani	2022	56
6	Addressing Barriers to Clinical Trial Participation for Transgender People With Cancer to Improve Access and Generate Data Journal of Clinical Oncology ·Ash B. Alpert, Jamie R. Brewer, Cristiane Goshc, Jeanette Jong Blomkvist, Ketino Pasenidou, John R. Blosnich, Susanne U. Miedlich, Charles Kamen, Don S. Dizon, Richard Pazdur, Julia A. Beaver, Lola A. Fashoyin‐Aje	2022	12
7	In search of autophagy biomarkers in breast cancer: Receptor status and drug agnostic transcriptional changes during autophagy flux in cell lines PLoS ONE ·Francesca Mascia, Ilya Mazo, Florian Andreas Beerlage, Konstantinos Karagiannis, Wells W. Wu, Rong‐Fong Shen, Julia A. Beaver, V. Ashutosh Rao	2022	11
8	FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review Clinical Cancer Research ·Thaís Valentini, Paz J. Vellanki, Nicole Drezner, Xiaoxue Li, Pallavi S. Mishra‐Kalyani, Yuan Li Shen, Huiming Xia, Yangbing Li, Jiang Liu, Jeanne Fourie Zirkelbach, Taherul Islam, В. МАССЕЛЬ Л, Qiuyi Choo, Fung Mei Ling, Ulrich‐Peter Rohr, 伸尚田中, Dianne Spillman, Richard Pazdur, Julia A. Beaver, Harpreet Singh	2021	42
9	The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology Clinical Cancer Research ·Julie A. Schneider, Yutao Gong, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Laleh Amiri‐Kordestani, Julia A. Beaver, Lola A. Fashoyin‐Aje, Nicole Gormley, Ahmad Thiab Albaw, Steven J. Lemery, Pallavi S. Mishra‐Kalyani, Gregory H. Reaman, Donna R. Rivera, Wendy S. Rubinstein, Harpreet Singh, Rajeshwari Sridhara, Richard Pazdur	2021	1
10	FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer The Oncologist ·Luckson Mathieu, Sujay Shah, Lee H. Pai-Scherf, Erin Larkins, Jonathon Vallejo, Xiaoxue Li, Lisa Rodríguez, Pallavi S. Mishra‐Kalyani, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Julia A. Beaver, Richard Pazdur, Harpreet Singh	2021	102
11	FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer Clinical Cancer Research ·Preeti Narayan, Christy Osgood, Harpreet Singh, Haw-Jyh Chiu, Tiffany K. Ricks, Edwin C.Y. Chow, Junshan Qiu, Pengfei Song, Jingyu Yu, Michael U. Ben Eli, O. O. Bublyk, Marija Vladimir Petrović-Ranđelović, William F. Pierce, Kirsten B. Goldberg, Shenghui Tang, Laleh Amiri‐Kordestani, Marc R. Theoret, Richard Pazdur, Julia A. Beaver	2021	118
12	Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis The Lancet Oncology ·Jennifer Gao, Joyce Cheng, Tatiana M. Prowell, Erik Bloomquist, Shenghui Tang, Suparna Wedam, Melanie Royce, RH Goldblatt, Christy Osgood, Gwynn Ison, Rajeshwari Sridhara, Richard Pazdur, Julia A. Beaver, Laleh Amiri‐Kordestani	2021	21
13	An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer Clinical Cancer Research ·Michael H. Brave, Chana Weinstock, Jamie R. Brewer, Muhammad Naufal Syaiful Haq, Daniel L. Suzman, Joyce Cheng, Lijun Zhang, Rajeshwari Sridhara, Amna Ibrahim, Paul G. Kluetz, Richard Pazdur, Julia A. Beaver	2020	20
14	U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program Clinical Cancer Research ·R. Angelo de Claro, Jennifer Gao, Tamy Kim, Paul G. Kluetz, Marc R. Theoret, Julia A. Beaver, Richard Pazdur	2020	12
15	CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis The Lancet Oncology ·Jennifer Gao, Joyce Cheng, Erik Bloomquist, Jaclyn Neel, Suparna Wedam, Harpreet Singh, Laleh Amiri‐Kordestani, Amna Ibrahim, Rajeshwari Sridhara, Kirsten B. Goldberg, Marc R. Theoret, Paul G. Kluetz, Gideon M. Blumenthal, Richard Pazdur, Julia A. Beaver, Tatiana M. Prowell	2019	194
16	FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy The Oncologist ·Daniel L. Suzman, Sundeep Agrawal, CS Wong, V. Ellen Maher, Laura L. Fernandes, Stella Karuri, Shenghui Tang, Rajeshwari Sridhara, Gift N. Lazarus, Kirsten B. Goldberg, Amna Ibrahim, Amy E. McKee, Richard Pazdur, Julia A. Beaver	2018	138
17	Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis The Lancet Oncology ·Julia A. Beaver, Maitreyee Hazarika, Flora Mulkey, Sirisha L. Mushti, Huanyu Chen, Kun He, Rajeshwari Sridhara, Kirsten B. Goldberg, Meredith K. Chuk, Paulette Mpaka-Nsenga, Jennie Chang, Amy Barone, Sanjeeve Balasubramaniam, Gideon M. Blumenthal, Patricia Keegan, Richard Pazdur, Marc R. Theoret	2018	112
18	An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies Clinical Cancer Research ·Julia A. Beaver, Abraham Tzou, Gideon M. Blumenthal, Amy E. McKee, Geoffrey Kim, Richard Pazdur, Reena Philip	2016	26
19	PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System Clinical Cancer Research ·Julia A. Beaver, John P. Gustin, Kyung Hee Yi, Anandita Rajpurohit, Matthew C. Thomas, Samuel F. Gilbert, David Rosen, Ben Ho Park, Josh Lauring	2013	76
20	The BOLERO-2 Trial: The Addition of Everolimus to Exemestane in the Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer Future Oncology ·Julia A. Beaver, Ben Ho Park	2012	91

About Julia A. Beaver

Julia A. Beaver is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Statistics and Probability and Economics and Econometrics, having authored 131 papers that have together received 4.8k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (36 papers), Cancer Immunotherapy and Biomarkers (27 papers), Health Systems, Economic Evaluations, Quality of Life (24 papers), Advanced Breast Cancer Therapies (18 papers), Lung Cancer Treatments and Mutations (16 papers), Economic and Financial Impacts of Cancer (15 papers), HER2/EGFR in Cancer Research (14 papers) and Biomedical Ethics and Regulation (13 papers). The work is most often cited by research in Oncology (2.7k citations), Cancer Research (1.1k citations), Pulmonary and Respiratory Medicine (1.5k citations), Statistics and Probability (267 citations) and Genetics (264 citations). Julia A. Beaver has collaborated with scholars based in United States, Canada and Singapore. Frequent co-authors include Richard Pazdur, Marc R. Theoret, Kirsten B. Goldberg, Rajeshwari Sridhara, Shenghui Tang, Paul G. Kluetz, Harpreet Singh, Laleh Amiri‐Kordestani, Lola A. Fashoyin‐Aje and Ben Ho Park. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, The Oncologist, JAMA Oncology and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact